Core Viewpoint - Sunshine Nuohong announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. to Beijing Zhongjian Peilian Medical Research Institute, aiming to enhance asset operation efficiency and reduce management costs due to the subsidiary's long-term losses [1][2]. Group 1: Equity Transfer Details - Sunshine Nuohong's subsidiary, Beijing Nuohong Demai Pharmaceutical Technology Co., Ltd., signed an equity transfer agreement, selling 70% of its stake in Meisuke Data for 2 million yuan [1]. - After the transaction, Sunshine Nuohong will no longer hold any equity in Meisuke Data, which will be excluded from the company's consolidated financial statements [1]. - The transfer involves part of the fundraising project "Clinical Trial Service Platform Construction Project," which has been completed and is now operational [1]. Group 2: Financial Implications - Meisuke Data has accumulated fundraising of 17.2887 million yuan, with 4.5 million yuan being registered capital paid by Nuohong Demai [1]. - The remaining 12.7789 million yuan of the fundraising will be returned to Sunshine Nuohong's fundraising account for future investment in the "Innovative Drug R&D Project" [2]. - The company aims to improve operational efficiency and support business expansion through this equity transfer, which is a strategic decision based on the company's current situation [2].

Core Viewpoint - Sunshine Nuohuo announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. to Beijing Zhongjian Peilian Medical Research Institute for a cash consideration of 2 million yuan, while another 30% equity was transferred for 0 yuan, resulting in the exclusion of Meisuke Data from the company's consolidated financial statements [1][1][1] Group 1: Company Transactions - The transaction involves the transfer of equity stakes in Meisuke Data, which was part of a previously completed fundraising project related to the "Clinical Trial Service Platform Construction Project" [1][1] - After the transaction, Sunshine Nuohuo's subsidiary, Nuohuo Demai, will no longer hold any equity in Meisuke Data [1][1] Group 2: Financial Performance - For the first half of 2025, Sunshine Nuohuo's revenue composition indicates that 99.91% of its income is derived from CRO (Contract Research Organization) business, with only 0.09% from other business activities [1][1] - As of the report date, Sunshine Nuohuo's market capitalization stands at 7.1 billion yuan [1][1]